List view / Grid view

Kristina Torfgard (IRLAB Therapeutics)

 

article

Drug candidates with blockbuster potential for CNS diseases

In this Q&A, Kristina Torfgård, CEO of IRLAB Therapeutics, discusses…

19 September 2024 | By

In this Q&A, Kristina Torfgård, CEO of IRLAB Therapeutics, discusses the Company’s current drug development pipeline, including two promising preclinical projects. Kristina also details their proprietary drug discovery and development platform which has enabled the production of many first-in-class candidates, and what she envisions for the future.